Drug Pharmacologically-Induced Mydriasis

Ryzumvi

Payments companies reported to CMS as associated with Ryzumvi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$709Kassociated payments (2023-2025)
4,739clinicians with associated payments
1company reporting

By year

2024 $147K
2025 $562K

Payments reported as associated with Ryzumvi, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Optometrist $176K
Ophthalmology $97K
Pediatrics $2,653
Cornea and External Diseases Specialist $2,250
Corneal and Contact Management $1,770
Glaucoma Specialist $1,390

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Ryzumvi

These are the largest totals companies reported as associated with Ryzumvi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Jay Pepose Chesterfield, MO $420,452.96
Peter Kollbaum Bloomington, IN Optometrist $48,000.00
John Rumpakis Lake Oswego, OR Optometrist $11,301.50
Alice Epitropoulos Columbus, OH Ophthalmology $9,947.77
Joseph Thimons Fairfield, CT Optometrist $3,573.90
Yun-Sen Chu Bloomington, MN Ophthalmology $2,850.00
Ranjan Malhotra Saint Louis, MO Ophthalmology $2,700.00
Mitchell Moffitt Twin Falls, ID Pediatrics $2,637.00
Carl Regillo Plymouth Meeting, PA Ophthalmology $1,650.00
Mile Brujic Bowling Green, OH Optometrist $1,359.21

Prescribed Ryzumvi?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.